Quick Answer
Entrada Therapeutics, Inc. reported Revenue (ASC 606) of $25.42 million for fiscal year 2025.
Entrada Therapeutics, Inc. Revenue (ASC 606) — Annual History
| Fiscal Year | Revenue (ASC 606) | YoY Change |
|---|---|---|
| 2025 | $25.42M | -87.9% |
| 2024 | $210.78M | +63.4% |
| 2023 | $129.01M | — |
Quarterly Revenue (ASC 606)
| Quarter Ending | Revenue (ASC 606) | YoY | QoQ |
|---|---|---|---|
| September 30, 2025 | $1.61M | -91.8% | -17.2% |
| June 30, 2025 | $1.95M | -97.9% | -90.5% |
| March 31, 2025 | $20.56M | -65.2% | +5.0% |
| September 30, 2024 | $19.57M | -55.3% | -79.3% |
| June 30, 2024 | $94.69M | +421.2% | +60.2% |
| March 31, 2024 | $59.12M | +134.0% | +35.2% |
| September 30, 2023 | $43.73M | — | +140.7% |
| June 30, 2023 | $18.17M | — | -28.1% |
- Entrada Therapeutics, Inc. showed a decrease of -87.9% in Revenue (ASC 606) compared to the prior fiscal year.
- Over the 2023–2025 period, Entrada Therapeutics, Inc.’s revenue (asc 606) has declined by 80.3% (from $129.01 million to $25.42 million).
- The most recent figure is from Entrada Therapeutics, Inc.’s fiscal year 2025 report (Form 10-K), filed with the SEC on February 26, 2026.
- All figures are sourced from SEC EDGAR XBRL filings, last verified June 17, 2026.
Last verified: